^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:Zaltrap (ziv-aflibercept IV) (VEGF-A inhibitor, PIGF inhibitor, VEGF-B inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Scottish Medicines Consortium
    Title:

    aflibercept (Zaltrap® ) is accepted for use within NHS Scotland.

    Published date:
    02/07/2014
    Excerpt:
    aflibercept (Zaltrap®) is accepted for use within NHS Scotland....in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin containing regimen.
    Secondary therapy:
    FOLFIRI
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    01/02/2013
    Excerpt:
    ZALTRAP in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
    Secondary therapy:
    FOLFIRI
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    08/03/2012
    Excerpt:
    ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.
    Secondary therapy:
    FOLFIRI
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Colorectal cancer...the panel added ziv-aflibercept as a second-line treatment option in combination with FOLFIRI or irinotecan only following progression on therapy not containing irinotecan.
    Secondary therapy:
    FOLFIRI; irinotecan
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Targeted Oncology
    Title:

    Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

    Published date:
    12/26/2015
    Excerpt:
    The Phase III VELOUR study demonstrated that the addition of aflibercept to second-line FOLFIRI in patients with mCRC significantly improved over all survival, progression-free survival and response compared with placebo.... After exclusion of the ARR, overall survival (OS) in the ITT minus ARR (ITT-ARR) population (N = 1102) was longer in the aflibercept plus FOLFIRI arm than in the placebo plus FOLFIRI arm...
    Secondary therapy:
    FOLFIRI
    DOI:
    https://doi.org/10.1007/s11523-015-0402-9
    Trial ID:
    VELOUR